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Abstract
Oral Mucositis is a condition seen in post-treatment mouth cancer patients and is a
condition of which the pathobiology is not entirely known. It is a condition that shares many
common pathways with other alimentary tract injuries such as inflammatory bowel disease.
Mathematical modeling of the system can help to identify gaps in the current knowledge base as
well as assist in generating new hypotheses and predicting clinical outcomes of conditions. A
detailed mathematical model would assist researchers in determining which drug targets are
worthwhile investigating. Deterministic modeling and Virtual Cell software were used to
assign rate constants to each pathway and define the model. The model was based on a
heterogeneous data set of both oral mucositis and inflammatory bowel disease subjects from both
human and animal models due to the lack of data from a single homogenous cohort. The model
although not capturing the transient dynamics of the data was able to come to a steady state for
eight of the nine network components as well as predict the steady state concentration within
error for six of eight of these components. This model will help to guide further investigation and
research in this field. It will also help to more fully understand the pathobiology of the condition
as well as assist in the development of new drugs that can help improve the quality of life
patients suffering from this very painful condition.
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Chapter 1: Introduction
Oral mucositis is a condition that is suffered by nearly all post radiation therapy and
chemotherapy patients. It is commonly referred to the most significant and debilitating acute
complication associated with radiation therapy and chemotherapy patients [1]. The condition
frequently develops seven to fourteen days after treatment is initiated and the outcome is a
variety of clinical and economic consequences. Oral mucositis can lead to a decrease in a
patient’s nutrition, daily functioning, and quality of life [2]. It can also lead to interruptions in
therapy, increased risk in subsequent treatments, and severe pain [1;3]. The disease is
characterized by ulcerations in the mucosa, giving rise to infection. These infections can have
possible fatal complications such as bacteremia and sepsis [2].
Economically, longer hospital stays and additional treatment can be very costly for the
patient. Patients displaying signs of ulceration on average incur charges of nearly $43,000 higher
than patients without ulceration [3]. Healing will eventually occur, but there will be residual
angiogenesis in the tissue and the chemical properties of the tissue that the patient started with
will not be the same as the properties of the tissue that the patient will end up with. Patients who
are at high risk for severe oral mucositis are those who have had previous infections, poor oral
hygiene, or prolonged treatments with steroids or comorbidities [4].
Development of a mathematical model describing the condition can have numerous
benefits. Through the development of the model, one can find gaps in the literature pertaining to
aspects of the network that are poorly understood. It would be very useful to identify these gaps
and then focus experimental work in these areas to gain a more complete understanding of how
network components influence each other. If a mathematical model of differential equations
describing the changes in protein concentration of network components over time is developed,
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one could predict what the concentration of a desired species will be at a certain time after
treatment. One could also model the effect that an experimental drug could potentially have on
the network and if it is worth taking the time to test the drug in an experimental drug trial.

Chapter 2: Background
Oral Cavity Mucositis
Oral cavity mucositis can occur when radiation therapy or chemotherapy is administered.
Patients receiving aggressive cancer treatment have a 40% chance to develop oral mucositis if
they are undergoing chemotherapy and have almost a 100% chance to develop oral mucositis if
they are undergoing radiation therapy, especially in combination with chemotherapy [3]. Due to
the tissue injury incurred during these treatments, the body’s ability to neutralize the reactive
oxygen species produced in overwhelmed [3]. The release of reactive oxygen species leads to a
multitude of tissue damaging events in the epithelium, endothelium, and connective tissues [2].
They also cause direct damage in cells, tissues, and blood vessels [1]. The cells of the mucosa are
especially vulnerable to the cytotoxic effects both radiation therapy and chemotherapy because
of the high turnover rates of the cells in the tissue [1]. Each cell will be replaced in 3 to 5 days
and the tissue as a whole will be replaced every 7 to 14 days [1].
Early research suggested that oral mucositis occurred only due to DNA injury in the
epithelium [1]. DNA injury in the epithelium leads to cell death and the thinning of the mucosal
epithelium. It was thought that this thinning of the epithelium was exclusively what leads to
ulceration in the mucosa [1]. It was later found that radiation therapy and chemotherapy induced
oral mucositis was not only due to injury in the epithelium but also due to events occurring in the
lower layers of tissue [3].
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In one such event, the transcription factor NF-κB is up-regulated leading to the
production of the pro-inflammatory cytokines IL-6, IL-1β, and TNF-α as well the production of
COX-2 from arachidonic acid [2;5]. In its inactive form, NF-κB is located in the cytoplasm
bound to unphosphorylated IκBα [6]. NF-κB is activated when reactive oxygen species, TNF-α,
or any other cellular signal leads to the activation of IκB kinase or IKK [6]. IKK will
phosphorylate IκBα leading to its degradation [6]. The degradation of IκBα activates NF-κB.
Activated NF-κB will enter the nucleus and trigger the transcription of many genes, including
the genes for IκBα and A20. IκBα will bind to NF-κB deactivating it and returning it to the
nucleus. A20 is responsible for inhibiting IKK [6]. Therefore, after an initial spike of activated
NF-κB, the up-regulation of inhibitory genes will lead to a decrease in the concentration of
activated NF-κB to a new steady state dependant on the presence of IKK producing signals.
COX-2 is an enzyme that leads to the production of prostaglandins such as PGE2, PGI2,
and TXA2 by catalyzing the synthesis of prostaglandins PGH2 and PGD2 from arachidinic acid
[5] [7]. PGH2 and PGD2 are quickly converted to PGE2, PGI2, and TXA2 by PGE synthase,
prostacyclin synthase, and thromboxane synthase respectively [8]. The production of these
prostaglandins are believed to cause inflammation, angiogenesis by activating vascular
endothelial growth factor, and even possibly feedback to produce more of the COX-2 enzyme
[5]. Prostaglandins also help protect the mucosa by inhibiting macrophages and T-cell responses
[7]. The pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 are believed to cause tissue injury
through the production of matrix metalloproteinases as well as assist in the further up-regulation
of the NF-κB transcription factor [1;2;9].
Tissue damage in the mucosa due to radiation therapy and chemotherapy can also be
caused through the ceramide pathway. Both radiation therapy and chemotherapy lead to the
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hydrolization of the cell-membrane lipid sphingomyelin through the activation of
sphingomyelinase and ceramide synthase [1]. Ceramide synthase or sphingomyelinase can
initiate the ceramide pathway, which leads to apoptosis [1;3]. It is probable that TNF-α
contributes to the upregulation of sphingomyelinase and helps promote apoptosis through the
ceramide pathway [10].
Finally, radiation therapy and chemotherapy causes the breakup of fibronectin in the
connective tissue [1]. The breakup of fibronectin stimulates macrophages, which in turn
stimulate matrix metalloproteinases (MMP’s) [1]. MMP’s cause direct tissue injury and also lead
to increased levels of TNF-α [1]. TNF-α and IL-1β in turn feedback and stimulate the
production of more MMP’s and therefore greater tissue injury [1].
The ulceration phase of oral mucositis begins when the tissue becomes sufficiently
damaged and gaps form in the tissue layers. Colonizing microorganisms then invade the tissue
and can cause life-threatening sepsis [1]. The products released by the microorganisms will lead
to the activation of macrophages, which in turn result in increasing levels of cytokines in the
tissue [1]. This is the most painful phase of the condition [1].
Tissue healing will naturally occur 3-6 weeks after the discontinuation of cancer
treatment [1]. Even though the tissue will heal and look normal, in fact many changes still are
present. There is residual change in the molecular and cellular environment as well as residual
angiogenesis [1;3]. Patients who have developed oral mucositis in the past will have increased
risk of developing oral mucositis again if radiation treatment or chemotherapy is needed again in
the future [1]. The pathology of the disease is summarized in Figure 1.
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Figure 1: Pathology of Oral Mucositis - The key species and interactions of oral mucositis are identified in this
network diagram. Radiation therapy (RT) and chemotherapy (CT) cause the up-regulation of reactive oxygen
species (ROS) which in turn leads to a cascade of events resulting in clonologic cell death, angiogenesis, apoptosis,
and tissue injury.

Oral mucositis will begin to manifest itself in radiation therapy patients when doses
approach 1000 to 2000 cGy [1]. It most commonly is manifested when doses exceed 3000 cGy,
and is almost certain to be manifested in patients receiving doses greater than 5000 cGy [1].
Symptoms develop within 7 to 14 days after the start of treatment and ulceration symptoms peak
5 to 6 weeks after the start of treatment [1;3].
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Inflammatory Bowel Disease
Inflammatory bowel disease is a condition that encompasses two different types of
chronic intestinal inflammation [11]. These two conditions are Crohn’s disease, which is
characterized by Th1 cytokines, and ulcerative colitis, which is characterized by Th2 cytokines
[12]. The pathology of inflammatory bowel disease and more specifically that of Crohn’s disease
share many common molecular pathways with the pathology of oral mucositis. A summary of
the pathology of Crohn’s disease can be seen in Figure 2.

Figure 2: Pathology of Inflammatory Bowel Disease (Crohn’s Disease) - The major species and interactions in
Crohn's disease are outlined in this network diagram. The activation and up-regulation of NF-κB by reactive oxygen
species and inflammatory cytokines leads to the production of more cytokines as well as the up-regulation of the
COX-2 pathway.

As in oral mucositis, the up-regulation of pro-inflammatory cytokines in inflammatory
bowel disease leads to tissue inflammation and damage [13;14;15]. Prominent cytokines up-

10
regulated in Crohn’s disease include IL-12, IL-18, IL-23, IFN-γ, as well as TNF-α, IL-1β, and
IL-6 [15;16;17]. Reactive oxygen species also contribute to the pathogenesis of inflammatory
bowel disease and in of themselves cause much tissue damage [18]. Reactive oxygen species
lead to the up-regulation of NF-κB in the gut, which in turn leads to the up-regulation of many
pro-inflammatory cytokines including the ones aforementioned [18;19]. Pro-inflammatory
cytokines, such as TNF-α, IL-1β, and IL-18, also lead to the up-regulation of more of the NF-κB
transcription factor, creating a positive feedback mechanism allowing for the perpetuation of
inflammation in the gut [15]. The tissue damaging effects of the pro-inflammatory cytokines
include the stimulation of myofibroblasts to synthesize increased amount of matrix
metalloproteinases, which causes mucosal degradation as they also do in observed mucositis in
the oral cavity [17]. Keratinocyte growth factor is also induced by cytokines, but primarily by
TNF-α, and it also produces changes in the gut [15]. One of these changes is the hyperplasia
observed in crypt cells in this condition [15].
The COX-2 enzyme has also been observed to be up-regulated by NF-κB in the mucosa
of inflammatory bowel disease patients as it has been observed in the mucosa of patients
suffering from oral mucositis [19]. Whereas COX-1 expression in inflammatory bowel disease
patients has been observed to be similar to that of patients without inflammatory bowel disease,
COX-2 expression increases from almost undetectable levels in normal mucosa to high levels
during the manifestation of inflammatory bowel disease [19]. With the up-regulation of COX-2
follows the up-regulation of prostaglandins such as PGE2, PGI2, and TXA2 [20]. The
prostaglandins participate in the regulation of cytokine production in mononuclear cells and
possible in lymphocytes and macrophages also [20]. It is also possible that the diarrhea caused
by inflammatory bowel disease may be in part due to increased prostaglandin production [20].
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Angiogenesis, or the production of new blood vessels, is also a symptom of inflammatory
bowel disease as it is in oral mucositis [14]. Angiogenesis is promoted through the production of
vascular endothelial growth factor (VEGF), which is up regulated by PGE2 [21;22].
Angiogenesis, while characteristic of inflammation, is required for the development and repair of
all tissues [21]. Without the induction of angiogenesis the spontaneous healing seen in oral
mucositis and in inflammatory bowel disease would not occur.
Deterministic Modeling
The common network can be modeled using deterministic modeling which will allow one
to observe the changes in concentration of the proteins involved in the network [23]. A system of
ordinary differential equations can be set up to model the change in protein concentration of a
network component per unit time as a function of components producing the protein and
components using up the protein. To specify the model rate constants are assigned to each
reaction pathway. In order to calculate the rate constants for all of the reactions, there must be
data available describing the dynamic behavior of the concentration of each protein in the
network over a period of time. Once the data is obtained, the program Virtual Cell can be used
to obtain estimates for each rate constant.
The Virtual Cell Software Package
The program Virtual Cell was instrumental in this research to estimate the rate
constants for a given data set. Virtual Cell is a computational environment which is designed
for cell biologists as well as for mathematical biologists and bioengineers to aid in the
construction of cell biological models and in the generation of simulations from them [24;25].
The program contains a biology-oriented graphical user interface, which allows one to assemble
a model by specifying the molecules, reactions, and structures involved [24]. It provides a
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framework for modeling biochemical, electrophysiological, and transport phenomena while still
taking into account the sub cellular localization of the molecules that take part in them [24].
The program allows the user to define both spatial and non-spatial models [24;25]. Using
spatial models, one can specify compartments and geometry, whereas using non-spatial models
one can create models assuming well-mixed compartments [24;25]. Once simulations are
produced, they can be compared to the experimental data. If the simulation matches the data,
new simulations can be run under different conditions to predict results [24]. Virtual Cell can
also be used to perform parameter estimation analyses after specification of a data set and a
model [25].

Chapter 3: Results
Model Development
Nine key components were identified in the COX-2 mediated oral mucositis network.
These components were NF-κB, COX-1, COX-2, TNF-α, IL-1β, IL-6, PGE2, PGI2, and TXA2.
The network showing the reactions and feedback loops interconnecting these nine components is
shown in Figure 3.
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Figure 3: Core Mucositis Network - The key species and interactions common to both the oral mucositis and
inflammatory bowel disease networks are captured in this diagram. The up-regulation of NF-κB by reactive oxygen
species and inflammatory cytokines leads to the production of more inflammatory cytokines as well as to the
production of prostaglandins by the COX-2 pathway.

The three feedback loops taken into account in the core network was the feedback of
TNF- α, IL-1β, and PGE2 to up-regulate more of the NF-κB transcription factor.
The Bio-model tool in Virtual Cell was used to input each species into a single
compartment entitled “Mucosa”. Reaction pathways were then mapped according to the network
previously discussed. Virtual Cell allows the user to specify the kinetics for each reaction
pathway connecting two components. For each reaction, mass-action kinetics was selected and a
rate constant was specified. A total of 27 unknown rate constants were assigned to the 27
reaction pathways in this network.
Each component in the oral mucositis network was modeled using an ordinary
differential equation describing the dynamic behavior of the species concentration over time.
Each differential equation was created by subtracting all of the terms that lead to the usage of the
species from all of the terms that lead to the production of the species. All species except for
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COX-1 are dependant on the concentration of another species in the network. The differential
equations describing the nine components in the network are as follows,
d[NF − κB]
= k1 + k 2 *[TNF − α ] + k 3 *[IL −1β ] + k 4 *[PGE − 2] − k 5 *[NF − κB]
dt
d[TNF − α ]
= k 6 + k 7 *[NF − κB] − k 8 *[TNF − α ]
dt
d[IL −1β ]
= k 9 + k10 *[NF − κB] − k11 *[IL −1β ]
dt
d[COX − 2]
= k12 − k13 *[COX − 2]
dt
d[COX −1]
= k14 − k15 *[COX −1]
dt
d[PGE − 2]
= k16 *[COX − 2] + k17 *[COX −1] − k18 *[PGE − 2]
dt
d[PGI − 2]
= k19 *[COX − 2] + k 20 *[COX −1] − k 21 *[PGI − 2]
dt
d[TXA − 2]
= k 22 *[COX − 2] + k 23 *[COX −1] − k24 *[TXA − 2]
dt
d[IL − 6]
= k 25 + k26 *[NF − κB] − k 27 *[IL − 6]
dt
Figure 4: Differential Equations Describing the Oral Mucositis Model - The nine key species of the mucositis are
modelled by the use of ordinary differential equations.

where the concentration of each of the nine species is modeled as a function of time. The units of
the concentrations of each species described by the differential equations are shown in Table1.
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Table 1: Concentration Units of Species in Model ODE’s
Species

Units

NF-κB

uM
day

TNF-α

mRNA _ norm _ to _ GAPDH
day

IL-1β

mRNA _ norm _ to _ GAPDH
day

COX-2

ng _ mRNA
day

COX-1

ng _ mRNA
day

PGE-2

pg /100mg _ tissue
day

PGI-2

pg /ml
day

TXA-2

pg /ml
day

IL-6

mRNA _ norm _ to _ GAPDH
day

The Bio-model in Virtual Cell was then used to generate a Math-model in the same
application. The Math-model in Virtual Cell generated a set of differential equations identical
to the set described in Figure 4 confirming their validity. In order to run a simulation in Virtual
Cell the rate constants needed to be specified. Since there were no literature values reported for
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any of the rate constants they had to be derived from the data collected from the literature using
the regression analysis tool in Virtual Cell.
Data Collection
In the literature survey it was found that there is very little published data concerning the
dynamics of any of the oral mucositis pathway components. Although it is preferable to use a
single homogenous cohort when developing a model such as this, the lack of necessary published
data made it necessary to collect a heterogeneous set of data. Using a systems biology approach,
one can collect data from a variety of similar conditions sharing the same pathway and integrate
the data to form a uniform computational model. Since inflammatory bowel disease and more
specifically Crohn’s disease shares the same pathway as oral mucositis, data was taken from
Crohn’s disease patients and animal models to help populate the model.
Gaps in the literature were also identified in the survey of inflammatory bowel disease.
After combination of oral mucositis data with inflammatory bowel disease data from both human
and animal models, it was found that there is still a lack of data describing the dynamics of PGI2
and TXA2. There is also very little data describing the dynamics of any of the network
components in oral mucositis alone.
It is difficult to measure the concentration of the NF-κB transcription factor in the cell
over time as once it is activated it is used up very quickly [6]. Data describing the dynamic
behavior of NF-κB was taken from a mathematical model created by Lipniacki et al to model
activate and inactive NF-κB in the cell after signaling from extracellular signals such as TNF-α
[6]. The model was based on a two-compartment system, the cytoplasm and the nucleus [6].
Since it is the free, activated NF-κB in the nucleus that leads to the up-regulation of the
inflammatory cytokines and COX-2, it was the free, active NF-κB data generated in the model
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that was used for the oral mucositis model. The model is based on the assumptions that hundreds
of mRNA transcripts can be translated per seconds and that the A20 inhibitor of IKK acts at the
level of IKK and not somewhere upstream of IKK [6].
Data describing the dynamic behavior of the TNF-α, IL-1β, and IL-6 cytokines was taken
from models of rat colitis induced by TNBS in 50% ethanol. 1.2 mL of the TNBS solution was
injected into the distal colon of the rats [26]. The data was gathered using a semi-quantitative
RT-PCR assay and the data was measured in the amount of cytokine mRNA relative to the
amount of GAPDH mRNA in the sample [26]. The section of the colon observed was the section
from the cecum to the anus [26]. Each experimental group anesthetized at each time point was
made up of a maximum of five animals [26]. The literature study utilized took data at the 0, 1, 7,
14, 28, and 45-day time points [26].
COX-1 and COX-2 data was taken from obtained clinical trial data [8]. In the trial there
were three patients. Samples were taken 10 days pre-radiation treatment, as well as 10, 28, and
100 days after the administration of the first dose of radiation therapy. Samples that were taken
were biopsy and blood samples from the bucal layer of the oral mucosa. The COX-1 and COX-2
data taken were measured in ng of mRNA.
Data regarding the dynamic behavior of prostaglandin E2 was found in the literature
where C57BL/6 mice were exposed to 3% (w/v) dextran sulfate sodium (DSS) to induce chronic
colitis [7]. The mice used in the study were 7-12 weeks old and weighed 18-22 g [7]. Data was
taken at times of 0, 1, 3, 5, 12, 19, 26, and 34 days. Samples were analyzed by ELISA and
protein values were measured in pg/100 mg of colonic tissue biopsied [7].
PGI2 and TXA2 data was found in the literature where epithelial and mononuclear cells
cells were isolated from intestinal mucosa in healthy and inflammatory bowel disease patients
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[27]. The study consisted of four Chron’s Disease patients who had not taken any steroids up to
one month prior to the operation [27]. Steroids may inhibit both of these prostaglandins [27].
Samples were determined using a radioimmunoassay and were measured in pg/ml [27]. Samples
were taken at assumed steady state levels. There was no data describing the dynamic data of
either PGI2 or TXA2. The data from this study suggested that enhanced synthesis of both PGI2
and TXA2 in inflammatory bowel disease is mainly due to increased synthesis of both PGI2 and
TXA2 in mononuclear cells [27]. There was a four-fold increase in the change in secretion of
PGI2 and TXA2 in mononuclear cells as compared to the change in epithelial cells [27].
Parameter Estimation
The parameter estimation tool in Virtual Cell was then used to analyze a data set and
predict values for all 27 rate constants. Initial guesses were taken from previously run regression
tests. Once the regression analysis tool had predicted a set of rate constants, a simulation was run
and the model was compared to the experimental data. The rate constants were then re-analyzed
using new initial guesses as well as any new data that became available. The most accurate set of
rate constants predicted by Virtual Cell, which were used in the simulation to generate the
model can be found in Table 2.
Table 2: Rate Constant Estimations for Model ODE’s
Rate Constant

Value

Units

Reference

k1

12.49

uM _ NF − κB
day

[6]

k2

10.10

uM _ NF − κB
day * mRNA

[6;26]

k3

12.21

uM _ NF − κB
day * mRNA

[6;26]

19
k4

2.71*10-6

uM _ NF − κB
day * pg /100mg _ tisue

[6;7]

k5

53.17

1
day

[6]

k6

463.67

mRNA _ norm _ GAPDH
day

[26]

k7

5.28*10-19

mRNA _ norm _ GAPDH
day * uM _ NF − κB

[6;26]

k8

1,269.85

1
day

[26]

k9

105.16

mRNA _ norm _ GAPDH
day

[26]

k10

100.97

mRNA _ norm _ GAPDH
day * uM _ NF − κB

[6;26]

k11

90.67

1
day

[26]

k12

119.97

ng _ mRNA
day * um _ NF − κB

[8]

k13

2.71

1
day

[8]

k14

1,738.18

ng _ mRNA
day

[8]

k15

6.12*10-18

1
day

[8]

k16

8.88*10-19

pg /100mg _ tissue
day * ng _ mRNA

[7;8]

k17

40.54

pg /100mg _ tissue
day * ng _ mRNA

[7;8]
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k18

0.04

1
day

[7]

k19

51.63

pg /ml
day * ng _ mRNA

[8;27]

k20

448.04

pg /ml
day * ng _ mRNA

[8;27]

k21

0.02

1
day

[27]

k22

55.59

pg /ml
day * ng _ mRNA

[8;27]

k23

3,675.93

pg /ml
day * ng _ mRNA

[8;27]

k24

0.03

1
day

[27]

k25

36.36

mRNA _ norm _ GAPDH
day

[26]

k26

56.80

mRNA _ norm _ GAPDH
day * uM _ NF − κB

[8;26]

k27

351.37

1
day

[26]

Literature Data vs. Model Predictions
Simulations in Virtual Cell were run using the Runge-Kutta-Fehlberg (Fifth Order,
Variable Time Step) solver. Each simulation was run from time t = 0 days to time t = 50 days.
The time interval was chosen to match the time interval over which the majority of the
experimental component data was specified. The simulation data generated from the model was
plotted and compared to the experimental and literature data collected.
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Figure 5: Dynamic Behavior of NF-κB - The NF-κB data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [6].

Figure 5 shows the comparison of the NF-κB model to the simulation data collected from
the literature. The NF-κB transcription factor was found in the literature to be up regulated to a
maximal concentration of approximately 0.28 uM in 1.25 hours [6]. It then falls to a steady state
concentration of 0.08 uM approximately 6 hours after initial activation [6]. The model was able
to closely approximate this behavior as the NF-κB reaches a plateau concentration at
approximately the same time and at a concentration of 0.083 uM.
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Figure 6: Dynamic Behavior of TNF-α - The TNF-α data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [26].

Figure 6 shows the comparison of the TNF-α model compared to the data found in the
literature. TNF-α was found in the literature to reach a peak concentration of 0.78 ± 0.2 units
mRNA norm to GAPDH in 1 day and then move to a steady state concentration of 0.35 ± 0.13
units mRNA norm to GAPDH in approximately 45 days [26]. The TNF-α model was very
inaccurate in describing the dynamic nature of the TNF-α literature data. The model predicts a
very fall rise to a plateau concentration of 0.362 units mRNA norm to GAPDH. The plateau
concentration of the model was very close to the steady state concentration of the data and was
able to predict it within error.
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Figure 7: Dynamic Behavior of IL-1β - The IL-1β data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [26].

Figure 7 displays the comparison of the literature data found for IL-1β to the model
generated to describe the species. The literature data collected for IL-1β shows that IL-1β is up
regulated very quickly. It plateaus and reaches a peak concentration of 1.3 ± 0.1 units mRNA
norm to GAPDH in 14 days [26]. It then falls and reaches a new steady state concentration of
0.95 ± 0.1 units mRNA norm to GAPDH at the 45 day mark. The IL-1β model while fails to
capture the dynamics of the data and it predicts a very quick rise to a plateau concentration. The
model reaches a plateau concentration of 1.103 units mRNA norm to GAPDH at the 0.1 day
mark which is much earlier than the data reaches the new steady state. In reaching this new
steady state at an earlier time point it also does not recognize any peak in IL-1β concentration
before it falls to the new steady state concentration. The plateau concentration of the model does
not accurately predict the steady state concentration of the data within error, but it falls just
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slightly above the upper range of acceptable error.

Figure 8: Dynamic Nature of COX-2 - The COX-2 data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [8].

Figure 8 shows the comparison between the literature data describing the dynamics of
COX-2 and the model generated to describe the behavior of COX-2. The COX-2 data gathered in
the clinical trial study was found to oscillate to a peak of 0.0677 ± 0.067 ng mRNA at t = 10 days
and then fall to 0.019 ± 0.0156 ng mRNA at t = 28 days. It then proceeds to rise again to 0.096 ±
0.102 ng mRNA at t = 100 days [8]. Steady state was assumed to have been reached after 100
days. The COX-2 model predicts a stable amount of COX-2 present in the mucosa over the
entire time range. No fluctuations or dynamic behavior of any kind is seen in the model. The
model reaches a plateau concentration of 0.09 ng mRNA which is slightly less than the steady
state concentration of COX-2 in the data set, but the prediction of the data by the model falls
within the acceptable error range.
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Figure 9: Dynamic Behavior of COX-1 - The COX-1 data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [8].

Figure 9 shows the comparison between the COX-1 model and the data gathered
describing the dynamics of COX-1 in the literature. The COX-1 data collected in the clinical trial
study was also found to oscillate much like the COX-2 data. The amount of COX-1 in the
mucosa increased to 0.853 ± 0.51 ng mRNA at t = 10 days. It then fell to 0.270 ± 0.042 ng
mRNA at t = 28 days before rising again to 0.443 ± 0.212 ng mRNA at t = 100 days [8]. Steady
state was again assumed to be reached by the 100-day mark. The COX-1 model does not capture
the dynamic nature of the experimental data, but it does reasonable predict the COX-1 steady
state concentration. The model predicts that the amount of COX-1 in the mucosa at steady state
will be 0.417 ng mRNA. The model also falls within the error bars for each experimental data
point except for the point at t = 28 days where the model falls just outside of the error bars.
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Figure 10: Dynamic Behavior of PGE2 - The PGE2 data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [7].

Figure 10 displays the literature data collected for PGE2 in comparison to the model
generated to describe the dynamics of PGE2. The PGE2 data found in the literature was highly
variable. The concentration of PGE2 initially decreases, but then rebounds to a peak
concentration of 3,800 ± 800 pg/100 mg colonic tissue at t = 19 days and then falls back to a new
steady state concentration of 2400 pg/100 mg colonic tissue [7]. The PGE2 model predicts a
steady decline of the species to a plateau concentration of 792.6 pg/100 mg colonic tissue. The
model fails to capture the dynamics of the literature data and it is not able to predict the final
steady state of the data within error.
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Figure 11: Dynamic Behavior of IL-6 - The IL-6 data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [26].

Figure 11 shows the IL-6 model generated in comparison to the literature data collected.
The literature data collected for IL-6 showed an initial spike from a very low initial
concentration of IL-6 to a concentration of 1.25 ± 0.1 units mRNA norm to GAPDH in 1 day
[26]. The concentration of IL-6 then fell and reached a new steady state at a concentration of 0.3
± 0.05 units mRNA norm to GAPDH [26]. The IL-6 model was not able to capture the dynamics
of the system or predict the steady state concentration of the species within error. The steady
state predicted by the model was 0.123 units mRNA norm to GAPDH, which was well just
below the uncertainty range of the literature value. The model was also not able to capture the
initial spike of IL-6 in the first few days after treatment.
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Figure 12: Dynamic Behavior of PGI2 - The PGI2 data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [27].

Figure 12 shows the PGI2 model in relation to the literature data accumulated for the
species. The only literature data gathered for PGI2 specified a normal concentration of PGI2 in
the mucosa, which is 6,926.4 ± 3,463.2 pg/ml, and a new steady state concentration of PGI2 in
the mucosa after the activation of the COX-2 pathway in inflammatory bowel disease [27]. As
occurs in the rest of the network, the new steady state was assumed to have been met by the 45day mark. The new steady state concentration of PGI2 is 10,389.6 ± 3,078.4 pg/ml [27]. The
PGI2 model predicts a rise to the new steady state concentration in about 33 days. It also predicts
the new steady state value of PGI2 as 8,548.39 pg/ml, which falls between the regions of
uncertainty in the literature data.
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Figure 13: Dynamic Behavior of TXA2 - The TXA2 data is compared against the Virtual Cell™ model simulation
where the blue markers represent the data and the green line represents the model simulation [27].

Figure 13 shows the model generated for TXA2 in relation to the literature data located
pertaining to TXA2. As with the PGI2 literature data, the data found in the literature describing
the behavior of TXA2 only specified a healthy concentration of TXA2 in the mucosa as well as a
new steady state concentration of TXA2 in the mucosa after the activation of the COX-2 pathway
in inflammatory bowel disease [27]. The healthy concentration of TXA2 in the mucosa is 7,696 ±
1,539.2 pg/ml and the new steady state after the activation of inflammatory bowel disease is
31,553.6 ± 11,544 pg/ml [27]. The TXA2 model predicts the concentration of TXA2 will increase
at a slower rate as time increases. Although the model reasonably predicts the new steady state to
be 37,704.64 pg/ml, which is within the range of uncertainty of the literature steady state value,
the dynamics that the model predicts are very unlikely. If the model were to continue to be valid
for later time points, the concentration of TXA2 would continue to increase to a plateau
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concentration, which will possibly be greater than the steady state of TXA2 within error.
In summary, seven of the nine major network components modeled reached a plateau
concentration. The only components not to reach a plateau concentration were PGE2 and TXA2.
Of the seven network components reaching steady state, the model was able to predict the steady
state of the species to within error in five cases.

Chapter 4: Discussion
The largest contributor to the model failing to capture the dynamics of the system is the
many gaps of knowledge in the literature. The lack of kinetic data in the literature is one of main
sources of error. When very little in the way of kinetics is specified, Virtual Cell™ cannot be
expected to capture them. Also, since the pathways of the network are still under investigation
and all feedback loops in the system have not yet been determined the specification of the
network to Virtual Cell™ may also be inaccurate. In fact, one the most important outcomes of
this investigation and development of this preliminary model is the identification of gaps in the
knowledge and prediction of feedback loops or pathways that seems to exist that have not been
previously identified.
As mentioned, no data was found describing the dynamics of PGI2 and TXA2 in
inflammatory bowel disease, and no data at all was found describing the dynamics of any of the
species in oral mucositis alone. Also, the data found in the literature describing the dynamics of
the species in inflammatory bowel disease was very few. Therefore, the need for new studies and
new data describing all of the species in the network are desperately needed. Central of the
network is the up-regulation of NF-κB and COX-2. No experimental data was found for the NFκB transcription factor. It is critical that further investigation is done into the dynamics of this
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component. The up-regulation of COX-2 follows the up-regulation of NF-κB. Accurately
understanding the nature of COX-2 protein concentrations throughout the tissue injury and tissue
healing process is critical as the COX-2 in the mucosa leads to the up-regulation of
prostaglandins and cytokines, which cause tissue damage and angiogenesis. Currently, the study
of COX-2 included in the model contains only three patients [8]. Data accumulated from three
patients is not enough to observe a trend in the data or understand the true dynamics of the
species. More data will need to be accumulated from more patients before the model will be able
to be made more accurate.
Finally, one additional element to be considered in future models is the effectiveness of a
COX-2 inhibitor in reducing the symptoms of oral mucositis. COX-2 inhibitors have been
proven in rat colitis models to reduce diarrhea and weight loss as well as cause a significant
reduction in colonic injury and PGE2 levels [28;29]. A full study into the molecular events
occurring in both oral mucositis and in inflammatory bowel disease could lead to a better
understanding of the effects of COX-2 on the mucositis network and could provide a comparison
to model predictions. Other therapeutic interventions studied for the treatment of oral mucositis
have been cryotherapy, growth factor treatment, anti-inflammatory agent treatment, antioxidant
treatment, antimicrobial agent treatment, and laser therapy [30]. As the model is developed,
predictions can be postulated as to the outcomes of these treatments and their relative
effectiveness, and data collected from these cases would go a long way in improving the current
knowledge of oral mucositis.
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Chapter 5: Conclusions
In conclusion, the preliminary mathematical model developed to describe the oral
mucositis network based on a heterogeneous set of data collected from literature studies of oral
mucositis as well as literature studies of inflammatory bowel disease in both human and animal
models was able to predict in five of nine cases the steady state concentration of the network
component. Although the model failed to capture the dynamics of the data collected, the
collection of more data as well as more investigation into the pathogenesis of both oral mucositis
and inflammatory bowel disease will likely yield more accurate results in the future.

Chapter 6: Future Recommendations
The current model can be improved in many ways, one of which is the accumulation of
data from a single cohort of test subjects. A more mature model based on a single homogenous
cohort will yield many benefits. Future laboratory work and clinical investigations will be greatly
accelerated, as the model will provide preliminary predictions of outcomes. Development of a
mature model will also shed light on the mechanisms by which oral mucositis is specific to
certain areas of the mucosa and why other non-oral mucosa are more resistant and rarely affected
by high-dose cancer radiation therapy and chemotherapy. A sensitivity analysis will be
conducted to analyze the accuracy of the model parameters. Other future work on the model
includes a stability analysis, which will test how stable the model is in response to perturbation.
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